- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02553044
Change in Free 25(OH)D After High Dose in Vitamin D Deficient Postmenopausal Women
Total 25(OH)D is currently used as a biomarker of vitamin D status. However, there is some debate as to whether total 25(OH)D is the best marker to use.
It has been suggested that free vitamin D may be better because it may be more biologically available.
There are also some uncertainties about how we treat vitamin D deficiency. A single dose is attractive because it is certain that the patient has had the dose and there is no requirement for ongoing compliance, but it is still not clear what the best dose is to give. Also, recent studies have highlighted that high dose vitamin D supplementation may increase the risk of falling in older populations.
The investigators believe that studying how free vitamin D responds to different bolus doses is the best way address some of the current research gaps, including what is the best biomarker of vitamin D status, what is the mechanism of vitamin D toxicity and what is a safe bolus dose to treat deficiency.
The investigators will study changes in total and free 25(OH)D, and also clinical response, to three different bolus doses of vitamin D (50 000IU, 150 000IU and 500 000IU) in 84 vitamin D deficient postmenopausal women, over a three month period with 5 study visits. A concurrent control group of 28 vitamin D sufficient postmenopausal women will also be recruited.
This will allow the investigators to determine how total and free vitamin D change with bolus dosing and whether there is a disproportionate rise in free 25(OH)D with higher doses that may lead to hypercalcemia and falls.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The most commonly used measurement of vitamin D status is serum 25-hydroxyvitamin D (25(OH)D). However there is no clear consensus on the level of 25(OH)D required to protect against adverse effects of deficiency.
One approach is to define deficiency is the level of 25(OH)D at which there is a secondary physiological response, such as a rise in parathyroid hormone. However, this approach has not yielded a clear answer. Total 25(OH)D below 30nmol/l is not always associated with an increased parathyroid hormone (PTH) response, and total 25(OH)D and PTH do not always respond to vitamin D supplementation. This suggests that total 25(OH)D measurement may not be the best biological marker of vitamin D status.
Vitamin D and its metabolites are bound to proteins in the circulation: around 85-90% of 25(OH)D is bound to vitamin D binding protein (DBP), 10-15% is bound to albumin, and less than 1% is in the free form. DBP protects 25(OH)D from degradation and allows a circulating store to accumulate.
The free hormone hypothesis suggests that only the unbound 'free' portion of protein bound hormones is biologically active, and that this should be measured for the accurate assessment of hormone availability. Calculated free 25(OH)D concentrations have been shown to be better correlated to bone mineral density (BMD) than total 25(OH)D in a healthy population and to be more closely related to PTH in patients with end stage renal disease.
The binding capacity of DBP may be overwhelmed in some situations. In female participants treated with an oral dose of 500,000 IU annually for 3 years there was an increase in the risk of falls and fractures that was particularly marked in the three month period after each dose. It has been proposed that there was vitamin D toxicity and possible hypercalcaemia during this period due to the binding capacity of DBP being overwhelmed by the large increase in 25(OH)D with a relatively greater increase in free 25(OH)D. However, free vitamin D and calcium were not measured in the study, so there is not yet evidence to support this hypothesis.
The investigators will study changes in total and free 25(OH)D, and clinical response to three different bolus doses of vitamin D (50,000 units, 150,000 units and 500,000 units) in 84 vitamin D deficient (<30nmol/l) postmenopausal women over three months. This will allow the investigators to determine how free and total 25(OH)D change with bolus dosing and whether there is a disproportionately high rise in free 25(OH)D with higher doses. This will also generate a better understanding of what the optimum bolus dose for treatment of vitamin D deficiency is and whether free 25(OH)D may be a better marker of vitamin D status in some situations.
Aims of the study:
- To determine the effect of three different vitamin D bolus doses on free 25(OH)D and total 25(OH)D in vitamin D deficient post-menopausal women.
- To determine the effect of different vitamin D bolus doses on parameters of calcium metabolism, bone turnover markers and physical function in vitamin D deficient post-menopausal women.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
South Yorkshire
-
Sheffield, South Yorkshire, United Kingdom, S5 7AU
- Clinical Research Facility
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Caucasian
- 25(OH)D < 30nmol/l for treatment groups or 25(OH)D >50nmol/l for control group
- BMI between 20 kg/m2 and 30kg/m2
- 55 years and over and postmenopausal (at least 5 years since last menstrual period)
- Able and willing to participate in the study and provide written informed consent.
Exclusion Criteria:
- History of any long term immobilization (duration greater than three months)
- Pre-diagnosed diabetes mellitus
- High trauma fracture or low trauma fracture less than one year prior to recruitment
- History of or current conditions known to affect vitamin D or bone metabolism, including:
Chronic renal disease Malabsorption syndromes Diagnosed endocrine disorders Hypercalcaemia Diagnosed restrictive eating disorder
- Use of medications or treatment known to affect vitamin D or bone metabolism such as bisphosphonates or anti-epileptic medication.
- Alcohol intake of greater than 21 units per week
- Holiday with significant sunlight exposure in the last six weeks
- Planned sun holiday within study period
- Abnormal clinical laboratory parameters that are assessed as clinically significant by the PI.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 50 000IU Vitamin D3
50 000IU oral vitamin D3 (cholecalciferol) administered at baseline only.
|
Oral vitamin D3 doses made up using 50 000IU ampules of vitamin D3 dissolved in 1ml of olive oil.
Other Names:
|
Experimental: 150 000IU Vitamin D3
150 000IU oral vitamin D3 (cholecalciferol) administered at baseline only.
|
Oral vitamin D3 doses made up using 50 000IU ampules of vitamin D3 dissolved in 1ml of olive oil.
Other Names:
|
Experimental: 500 000IU Vitamin D3
500 000IU oral vitamin D3 (cholecalciferol) administered at baseline only.
|
Oral vitamin D3 doses made up using 50 000IU ampules of vitamin D3 dissolved in 1ml of olive oil.
Other Names:
|
No Intervention: Concurrent Control
Control group to receive no intervention.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Free 25(OH)D
Time Frame: Baseline to visit 3 (5-7 days after administration)
|
Change in free 25(OH)D from baseline to visit 3 (5-7 days after administration)
|
Baseline to visit 3 (5-7 days after administration)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of total 25(OH)D to free 25(OH)D
Time Frame: 5(+/-2) days, 28(+/-3) days and 84(+/-5) days
|
Between-group difference in proportion of serum free 25(OH)D to total 25(OH)D at 5, 28 days and 84 days
|
5(+/-2) days, 28(+/-3) days and 84(+/-5) days
|
1, 25(OH)2D
Time Frame: 5(+/-2) days, 28(+/-3) days and 84(+/-5) days
|
Between-group difference in 1, 25(OH)2D at 5, 28 days and 84 days
|
5(+/-2) days, 28(+/-3) days and 84(+/-5) days
|
Ionized calcium
Time Frame: 5(+/-2) days, 28(+/-3) days and 84(+/-5) days
|
Between-group difference in ionized calcium at 5, 28 days and 84 days
|
5(+/-2) days, 28(+/-3) days and 84(+/-5) days
|
Parathyroid Hormone
Time Frame: 5(+/-2) days, 28(+/-3) days and 84(+/-5) days
|
Between-group difference in PTH at 5, 28 days and 84 days
|
5(+/-2) days, 28(+/-3) days and 84(+/-5) days
|
Bone turnover marker - Alkaline Phosphatase
Time Frame: 5(+/-2) days, 28(+/-3) days and 84(+/-5) days
|
Between group difference in alkaline phosphatase at 5, 28 and 84 days
|
5(+/-2) days, 28(+/-3) days and 84(+/-5) days
|
Bone turnover marker - CTX
Time Frame: 5(+/-2) days, 28(+/-3) days and 84(+/-5) days
|
Between group difference in CTX at 5, 28 and 84 days
|
5(+/-2) days, 28(+/-3) days and 84(+/-5) days
|
Bone turnover marker - PINP
Time Frame: 5(+/-2) days, 28(+/-3) days and 84(+/-5) days
|
Between group difference in PINP at 5, 28 and 84 days
|
5(+/-2) days, 28(+/-3) days and 84(+/-5) days
|
Bone turnover marker - Osteocalcin
Time Frame: 5(+/-2) days, 28(+/-3) days and 84(+/-5) days
|
Between group difference in Osteocalcin at 5, 28 and 84 days
|
5(+/-2) days, 28(+/-3) days and 84(+/-5) days
|
Repeated chair stand test score
Time Frame: 5(+/-2) days, 28(+/-3) days and 84(+/-5) days
|
Between group difference in repeated chair stand test score at 5, 28 and 84 days
|
5(+/-2) days, 28(+/-3) days and 84(+/-5) days
|
Tandem stand balance test score
Time Frame: 5(+/-2) days, 28(+/-3) days and 84(+/-5) days
|
Between group difference in tandem stand balance test score at 5, 28 and 84 days
|
5(+/-2) days, 28(+/-3) days and 84(+/-5) days
|
8-feet walk course test score
Time Frame: 5(+/-2) days, 28(+/-3) days and 84(+/-5) days
|
Between group difference in 8-feet walk course test score at 5, 28 and 84 days
|
5(+/-2) days, 28(+/-3) days and 84(+/-5) days
|
Laying blood pressure
Time Frame: 5(+/-2) days, 28(+/-3) days and 84(+/-5) days
|
Between group difference in laying blood pressure at 5, 28 and 84 days
|
5(+/-2) days, 28(+/-3) days and 84(+/-5) days
|
Standing blood pressure
Time Frame: 5(+/-2) days, 28(+/-3) days and 84(+/-5) days
|
Between group difference in standing blood pressure at 5, 28 and 84 days
|
5(+/-2) days, 28(+/-3) days and 84(+/-5) days
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Jennifer Walsh, MBChB, PhD, University of Sheffield
Publications and helpful links
General Publications
- Sanders KM, Stuart AL, Williamson EJ, Simpson JA, Kotowicz MA, Young D, Nicholson GC. Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial. JAMA. 2010 May 12;303(18):1815-22. doi: 10.1001/jama.2010.594. Erratum In: JAMA. 2010 Jun 16;303(23):2357.
- Shibli-Rahhal A, Paturi B. Variations in parathyroid hormone concentration in patients with low 25 hydroxyvitamin D. Osteoporos Int. 2014 Jul;25(7):1931-6. doi: 10.1007/s00198-014-2687-4. Epub 2014 Mar 20.
- Powe CE, Ricciardi C, Berg AH, Erdenesanaa D, Collerone G, Ankers E, Wenger J, Karumanchi SA, Thadhani R, Bhan I. Vitamin D-binding protein modifies the vitamin D-bone mineral density relationship. J Bone Miner Res. 2011 Jul;26(7):1609-16. doi: 10.1002/jbmr.387. Erratum In: J Bone Miner Res. 2012 Jun;27(6):1438.
- Bhan I, Powe CE, Berg AH, Ankers E, Wenger JB, Karumanchi SA, Thadhani RI. Bioavailable vitamin D is more tightly linked to mineral metabolism than total vitamin D in incident hemodialysis patients. Kidney Int. 2012 Jul;82(1):84-9. doi: 10.1038/ki.2012.19. Epub 2012 Mar 7.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Metabolic Diseases
- Nutrition Disorders
- Musculoskeletal Diseases
- Avitaminosis
- Deficiency Diseases
- Malnutrition
- Bone Diseases
- Bone Diseases, Metabolic
- Vitamin D Deficiency
- Osteoporosis
- Physiological Effects of Drugs
- Micronutrients
- Vitamins
- Bone Density Conservation Agents
- Calcium-Regulating Hormones and Agents
- Vitamin D
- Cholecalciferol
Other Study ID Numbers
- STH18850
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Vitamin D Deficiency
-
University Hospital, Clermont-FerrandTerminated
-
Rajavithi HospitalQueen Sirikit National Institute of Child HealthCompleted
-
Universidade de Passo FundoUnknownDeficiency, Vitamin DBrazil
-
Federal University of Rio Grande do SulCompletedDeficiency, Vitamin DBrazil
-
Nutrition Institute, SloveniaEuropean Regional Development Fund; Vizera d.o.o.; Frutarom Etol d.o.o.CompletedVitamin B 12 Deficiency | Vitamin d Deficiency | Protein DeficiencySlovenia
-
Wageningen UniversityDSM Nutritional Products, Inc.; Top Institute Food and NutritionCompletedElderly, Frail | Deficiency, Vitamin DNetherlands
-
University of PaviaIstituti Clinici Scientifici Maugeri SpAUnknownVitamin D Deficiency | Vitamin D3 Deficiency | Vitamin DItaly
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNot yet recruitingVitamin d DeficiencyChina
-
Okan UniversityArçelik A.Ş.Completed
-
Brigham and Women's HospitalCompletedVitamin d Deficiency
Clinical Trials on Cholecalciferol (Vitamin D3)
-
Medical University of South CarolinaThrasher Research FundCompletedVitamin D Deficiency | PregnancyUnited States
-
Medical University of South CarolinaEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompleted
-
Mahidol UniversityUnknownCritical Illness | Vitamin D Deficiency | SarcopeniaThailand
-
Brigham and Women's HospitalNational Heart, Lung, and Blood Institute (NHLBI)Active, not recruiting
-
Medical University of South CarolinaEunice Kennedy Shriver National Institute of Child Health and Human Development...Completed
-
University of California, San FranciscoCompletedUlcerative Colitis (UC) | Crohn's Disease (CD)United States
-
National Institute of Allergy and Infectious Diseases...Autoimmunity Centers of ExcellenceTerminatedSystemic Lupus ErythematosusUnited States
-
Sanjay Gandhi Postgraduate Institute of Medical...CompletedPancreatitis, ChronicIndia
-
Atlanta VA Medical CenterCompletedVitamin D Deficiency | Chronic Kidney DiseaseUnited States
-
University of PittsburghNational Heart, Lung, and Blood Institute (NHLBI)CompletedCystic Fibrosis | Allergic Bronchopulmonary AspergillosisUnited States